Halozyme Therapeutics (HALO) Comprehensive Income (Loss), Net of Tax, Attributable to Parent — Quarterly & Annual

Screener

Comprehensive Income (Loss), Net of Tax, Attributable to Parent at other companies

Aquestive Therapeutics, Inc.AQST

-$22.86M-68.8%

Ionis PharmaceuticalsIONS

-$117.52M-194%

BioCryst PharmaceuticalsBCRX

$78.24M+1,297%

RegenxbioRGNX

$22.7M+132%

West Pharmaceutical ServicesWST

——

Arrowhead ResearchARWR

——

Other financials

Income statement

Revenue$481.0M+47.7%

Gross profit$401.8M+43.8%

Operating income$287.7M+42.1%

Net income$229.9M+39.2%

EPS (diluted)$1.90+42.9%

Balance sheet

Cash & equivalents$164.0M+165%

Total debt$2.2B+41.6%

Total equity$143.5M-56.9%

Total assets$2.6B+25.5%

Cash flow

Operating cash flow$240.9M+142%

CapEx$4.2M+167%

Free cash flow$236.7M+141%

Valuation

Market cap$12.23B+66.3%

Enterprise value$14.25B+61.3%

P/E17×-4.9×

P/S7.4×+1.1×

Profitability

Gross margin82.4%-1.8pp

Operating margin59.3%+9.0pp

Net margin47.9%+6.5pp

FCF margin48.5%+2.6pp

Returns & leverage

Return on equity124.5%+12.7pp

Debt / equity15.2×+10.6×

Current ratio2.7×-5.7×

Where this comes from

Reported directly by Halozyme Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:ComprehensiveIncomeNetOfTax.

The source filing: Halozyme Therapeutics’s 10-Q, filed August 6, 2026.

Filed: Aug 6, 2026, 4:11 PM EDT
Fiscal quarter: Q2 FY2026
Calendar quarter: Q2 2026
Accession: 0001159036-26-000104

Line item	Three Months Ended / June 30, 2026	Three Months Ended / June 30, 2025	Six Months Ended / June 30, 2026	Six Months Ended / June 30, 2025
Net income	$229,913	$165,160	$379,962	$283,255
Other comprehensive income
Unrealized (loss) gain on marketable securities, net	(73)	(35)	(76)	154
Foreign currency translation adjustment	(29)	(3)	16	(3)
Unrealized gain (loss) on derivative instruments, net	4,161	(27,047)	8,183	(34,270)
Realized loss on derivative instruments, net	814	2,095	2,138	1,887
Comprehensive income	$234,786	$140,170	$390,223	$251,023

Item 1. Financial Statements

FAQ

What is Halozyme Therapeutics's comprehensive income (loss), net of tax, attributable to parent?: Halozyme Therapeutics (HALO) reported comprehensive income (loss), net of tax, attributable to parent of $234.79M in Q2 2026.
How has Halozyme Therapeutics's comprehensive income (loss), net of tax, attributable to parent changed year-over-year?: Halozyme Therapeutics's comprehensive income (loss), net of tax, attributable to parent increased by 67.5% year-over-year, from $140.17M to $234.79M.
What does comprehensive income (loss), net of tax, attributable to parent mean?: Comprehensive Income (Loss), Net of Tax, Attributable to Parent

Ask your AI about Halozyme Therapeutics's comprehensive income (loss), net of tax, attributable to parent.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk